What question did this study set out to answer?

This case report aims to highlight the occurrence of tumor lysis syndrome in a patient with metastatic colorectal cancer following chemotherapy.

June 20, 2026Open Access

An uncommon encounter with tumor lysis syndrome in colorectal cancer

Puntos clave

This case report aims to highlight the occurrence of tumor lysis syndrome in a patient with metastatic colorectal cancer following chemotherapy.
Reported a case of a 61-year-old male with CRC and extensive liver metastases.
Monitored for symptoms of TLS after initiating FOLFOX chemotherapy.
Administered intravenous fluids, rasburicase, and febuxostat for treatment.
Patient developed acute TLS within 48 hours of chemotherapy, experiencing acute kidney injury and metabolic disturbances.
TLS treatment led to a rapid resolution of symptoms; however, the patient died 14 days later from metastatic disease complications.

Resumen

Tumor lysis syndrome (TLS) is a rare but life-threatening complication in solid tumors such as colorectal cancer (CRC). We report a 61-year-old male with metastatic CRC and extensive liver metastases who developed acute TLS within 48 hours of initiating FOLFOX chemotherapy. He presented with acute kidney injury (AKI), hyperuricemia, hyperphosphatemia, hypocalcemia, and elevated liver enzymes. Prompt treatment with intravenous fluids, rasburicase, and febuxostat led to rapid resolution of TLS. Despite recovery, the patient died two weeks later from complications of advanced metastatic disease. This case highlights the need for early TLS recognition in high-risk CRC patients.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Matos et al. (Thu,) studied this question.

synapsesocial.com/papers/6a362ebddb0793dc1a5366e2 https://doi.org/https://doi.org/10.3205/000361

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo